预约演示
更新于：2025-08-05
Levosimendan
左西孟旦
更新于：2025-08-05
概要
基本信息
药物类型 小分子化药 |
别名 Daxim、Levosimendan (USAN/INN)、NSC-759644 + [8] |
靶点 |
作用方式 抑制剂 |
作用机制 PDE3抑制剂(磷酸二酯酶3抑制剂) |
在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 奥地利 (2001-04-10), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C14H12N6O |
InChIKeyWHXMKTBCFHIYNQ-SECBINFHSA-N |
CAS号141505-33-1 |
关联
171
项与 左西孟旦 相关的临床试验CTRI/2025/03/083025
Comparison Of Efficacy Of Levosimendan Versus Milrinone In Catecholamine Resistant Septic Shock With Myocardial Dysfunction In Children : A Single-Center, Open-Label Randomized controlled Trial - Nil
NCT06478667
The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity: A Randomized Controlled Trial
ChiCTR2400091067
Clinical analysis of Levosimendan associated arrhythmia in Heart Failure patients
100 项与 左西孟旦 相关的临床结果
登录后查看更多信息
100 项与 左西孟旦 相关的转化医学
登录后查看更多信息
100 项与 左西孟旦 相关的专利（医药）
登录后查看更多信息
2,181
项与 左西孟旦 相关的文献（医药）2025-08-01JOURNAL OF SURGICAL RESEARCH
Effects of Levosimendan on Anastomotic Healing in an Ischemic Colon Anastomosis Model
Article
作者: Köktürk, Fürüzan ; Karakaya, Kemal ; Güven, Berrak ; Seven, Turan Eray ; Baş, Yilmaz
INTRODUCTION:
Anastomotic leakage following ischemic colon anastomosis poses significant morbidity and cost. Levosimendan, with inotropic and vasodilatory properties, may enhance healing. This study evaluated Levosimendan's effects on ischemic colon anastomosis in rats.
METHODS:
Sixty Wistar Albino rats underwent ischemic colon anastomosis and were randomized into six groups: fourth-day control, seventh-day control, fourth-day low-dose Levosimendan, seventh-day low-dose Levosimendan, fourth-day high-dose Levosimendan, and seventh-day high-dose Levosimendan. Anastomotic bursting pressure, myeloperoxidase, hydroxyproline levels, and histopathological changes were assessed.
RESULTS:
Levosimendan, particularly at low doses, significantly increased bursting pressure. The fourth-day low-dose group showed a median (Q1-Q3) bursting pressure of 98.00 (72.00-106.00) mmHg, compared to 53.00 (24.75-64.75) mmHg in the fourth-day control group (P = 0.001). The seventh-day low-dose group had a median (Q1-Q3) bursting pressure of 111.50 (96.50-154.00) mmHg, while the seventh-day control group had 91.00 (59.00-100.50) mmHg (P = 0.007). Histopathology revealed significant improvements in fibrosis (P = 0.020), ischemic necrosis (P < 0.001), and inflammatory cell infiltration in Levosimendan groups. Myeloperoxidase levels were significantly higher in the fourth-day low-dose group compared to the fourth-day control group (P = 0.041), while hydroxyproline levels showed no significant differences.
CONCLUSIONS:
Levosimendan positively impacts ischemic colon anastomosis healing in rats, particularly at low doses.
2025-08-01EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
Afterload mismatch after transcatheter edge‐to‐edge repair in functional mitral regurgitation: A propensity‐score matched analysis
Article
作者: Boretto, Paolo ; Frea, Simone ; Montonati, Carolina ; Crimi, Gabriele ; Cavallone, Elena ; De Ferrari, Gaetano Maria ; D'Ascenzo, Fabrizio ; Giannini, Francesco ; Biasco, Luigi ; De Filippo, Ovidio ; Raineri, Claudia ; Pedrazzini, Giovanni ; Reimers, Bernhard ; Bocchino, Pier Paolo ; Mangieri, Antonio ; Giovannini, Davide ; Dusi, Veronica ; Angelini, Filippo ; Tarantini, Giuseppe ; Pavon, Anna Giulia ; Gallone, Guglielmo ; Pidello, Stefano ; Mandurino Mirizzi, Alessandro
Abstract:
Background:
Transcatheter edge‐to‐edge repair (TEER) for severe functional mitral regurgitation (FMR) in patients with reduced left ventricular ejection fraction (LVEF) may lead to an acute increase in left ventricular afterload, termed afterload mismatch (AM). This study aimed to redefine AM clinically, analyse its determinants, and assess its prognostic impact post‐TEER in FMR patients.
Methods:
A multicenter case–control study was conducted, involving FMR patients with LVEF ≤35% undergoing TEER. AM post‐TEER was defined as the acute (within 24 h) need for escalation of inotropic or mechanical circulatory support. Sixty‐eight AM cases were compared with 68 propensity‐matched patients. Primary endpoints included in‐hospital mortality post‐TEER and 2‐year all‐cause mortality.
Results:
Median age was 68 years, 76% male. Procedural success was achieved in 92% of patients. Proportionate MR was associated with a higher risk of AM (adj‐HR 1.6, 95% CI 1.01–2.6, p = .04). Conversely, pretreatment with levosimendan (adj‐HR .29, 95% CI .12–.70, p < .01) and higher furosemide dose (adj‐HR per furosemide 10 mg increase .86, 95% CI .76–.98, p = .03) were protective. In‐hospital mortality was higher in the AM cohort (10% vs. 2%, p = .03), while 2‐year mortality rates were similar (34% vs. 20%, p = .09). Multivariable analysis revealed higher AM grades and post‐procedural MR as predictors of in‐hospital mortality and lack of procedural success for 2‐year mortality.
Conclusions:
Among patients with LVEF ≤35% and severe FMR undergoing TEER, AM was associated with in‐hospital mortality but did not impact long‐term outcomes. Proportionate MR increased the risk of AM, while pretreatment with levosimendan and higher furosemide doses was protective.
2025-08-01INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
Serum potassium is a critical risk factor for cardiac arrhythmias in acute heart failure patients treated with levosimendan: A retrospective study in a cohort of 250 patients
Article
作者: Wang, Xiaowu ; Liu, Wenguang ; Wu, Dong ; Ning, Bin ; Ma, Zhen
OBJECTIVES:
This study aimed to investigate the risk factors associated with developing cardiac arrhythmias in patients with acute heart failure treated with levosimendan.
MATERIALS AND METHODS:
A retrospective analysis was conducted in patients diagnosed with acute heart failure or acute exacerbation of chronic heart failure treated with levosimendan. The patients were divided into arrhythmia and non-arrhythmia groups based on the presence of rapid-type arrhythmias. Logistic regression analysis was used to identify independent risk factors for levosimendan-induced arrhythmias.
RESULTS:
Among the 250 patients, 49 (19.60%) experienced nine types of cardiac arrhythmias, the most common being atrial fibrillation (28.57%). The highest incidence of arrhythmias occurred within 48 hours of levosimendan infusion (77.6%). Multivariate analysis indicated that the lowest serum potassium concentration within 5 days after drug administration (odds ratio (OR) 0.410, p = 0.010, 95% confidence interval (CI) 0.209 - 0.805), micro-pump speed of > 0.2 μg/kg/min (OR 3.106, p = 0.039, 95% CI 1.584 - 11.789), and concomitant use of drugs that prolong the QT interval (OR 4.226, p = 0.001, 95% CI 1.850 - 9.657) were independent risk factors for levosimendan-induced arrhythmias. The incidence of arrhythmias increased when the lowest serum potassium concentration within 5 days after drug administration was below 3.94 mmol/L.
CONCLUSION:
This study identified risk factors associated with levosimendan-induced arrhythmias. Clinicians should monitor at-risk patients when administering levosimendan. When using levosimendan in clinical practice, it is necessary to maintain a serum potassium concentration above 3.94 mmol/L.
100 项与 左西孟旦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 阿根廷 | 2002-07-20 | |
| 急性失代偿性心力衰竭 | 奥地利 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 塞浦路斯 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 芬兰 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 希腊 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 冰岛 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 意大利 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 挪威 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 葡萄牙 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 西班牙 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 瑞典 | 2001-04-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 射血分数保留型心力衰竭 | 临床3期 | 美国 | 2024-01-10 | |
| 射血分数保留型心力衰竭 | 临床3期 | 美国 | 2024-01-10 | |
| 射血分数保留型心力衰竭 | 临床3期 | 加拿大 | 2024-01-10 | |
| 射血分数保留型心力衰竭 | 临床3期 | 加拿大 | 2024-01-10 | |
| 射血分数降低的心力衰竭 | 临床3期 | 美国 | 2024-01-10 | |
| 射血分数降低的心力衰竭 | 临床3期 | 美国 | 2024-01-10 | |
| 射血分数降低的心力衰竭 | 临床3期 | 加拿大 | 2024-01-10 | |
| 射血分数降低的心力衰竭 | 临床3期 | 加拿大 | 2024-01-10 | |
| 肺性高血压 | 临床3期 | 美国 | 2024-01-10 | |
| 肺性高血压 | 临床3期 | 美国 | 2024-01-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 349 | 艱艱壓蓋積繭壓築積範(鹹積廠窪網餘鏇獵鹽顧) = 鹹壓廠鬱繭鹽鹹憲鬱壓 鹽範鏇積繭觸構鹽築淵 (糧願淵鏇顧壓顧鹽積夢 ) | 积极 | 2024-09-02 | |||
Dobutamine alone | 艱艱壓蓋積繭壓築積範(鹹積廠窪網餘鏇獵鹽顧) = 淵齋襯壓構網膚選衊鹹 鹽範鏇積繭觸構鹽築淵 (糧願淵鏇顧壓顧鹽積夢 ) | ||||||
临床2期 | 44 | (Levosimendan 2.5mg/mL Injectable Solution) | 齋顧壓鹹廠衊網餘築積(鏇選襯獵獵簾範簾網構) = 築構鑰遞鬱醖衊憲鑰鑰 膚構繭醖構醖糧齋範築 (窪遞願構窪鬱選構襯廠, 10.07) 更多 | - | 2024-05-14 | ||
Matching Placebo (Matching Placebo) | 齋顧壓鹹廠衊網餘築積(鏇選襯獵獵簾範簾網構) = 願壓醖醖觸鏇築糧築壓 膚構繭醖構醖糧齋範築 (窪遞願構窪鬱選構襯廠, 7.87) 更多 | ||||||
N/A | - | Levosimendan intermittent infusions | 壓顧蓋鏇艱繭壓觸選遞(繭衊糧簾膚鏇範窪範醖) = 鹽鑰簾膚醖鹹繭艱窪鏇 鹽襯範選衊鬱蓋膚廠齋 (製築築願繭廠壓觸繭膚, 8) | - | 2024-05-13 | ||
N/A | - | - | Intermittent levosimendan infusion every 2 weeks | 壓蓋鬱願壓製齋遞襯範(齋夢夢鏇願鹹齋積淵繭) = 選蓋築鑰醖衊鏇繭鏇窪 構獵獵範憲衊鬱網鏇願 (鑰願遞願淵觸衊顧簾觸 ) 更多 | - | 2024-05-13 | |
N/A | - | 醖廠遞觸鏇鏇鏇齋遞艱(鏇築觸淵鏇糧廠醖願餘) = 1 patient (3.8%) 遞廠壓膚鏇鏇範鬱壓襯 (餘繭窪窪齋襯繭膚範艱 ) 更多 | - | 2024-05-12 | |||
临床2期 | 72 | (Milrinone) | 鏇夢糧蓋選鑰築簾獵艱(積簾選鏇築遞選壓壓獵) = 鹽餘蓋蓋鑰鹹築獵餘夢 艱膚鹹構衊淵齋鹹遞鏇 (齋衊憲壓願衊膚廠壓齋, 6.1) 更多 | - | 2024-03-26 | ||
(Levosimendan) | 鏇夢糧蓋選鑰築簾獵艱(積簾選鏇築遞選壓壓獵) = 積壓夢餘艱艱願觸繭簾 艱膚鹹構衊淵齋鹹遞鏇 (齋衊憲壓願衊膚廠壓齋, 5.9) 更多 | ||||||
N/A | 195 | Intermittent and scheduled levosimendan | 鹽艱築夢窪餘鑰壓築製(窪顧遞鹽繭簾醖網糧齋) = 壓選齋築鹽鏇壓顧顧醖 廠憲鏇膚壓艱窪襯鬱積 (範簾艱蓋構膚築選獵艱 ) 更多 | 积极 | 2023-05-21 | ||
临床3期 | 227 | 艱膚壓範膚獵艱構選築 = 築蓋壓鑰顧壓積範襯遞 膚蓋製網醖網淵壓鬱鏇 (鏇願襯鹹選廠鬱鹹憲醖, 齋齋壓齋繭範願壓襯願 ~ 構壓廠築廠艱簾鹽願蓋) 更多 | - | 2023-03-09 | |||
临床3期 | 496 | 壓夢膚顧餘襯網鑰鏇膚(糧遞願壓壓蓋蓋繭鏇顧) = 遞艱膚淵鑰艱廠觸壓鬱 願蓋鏇憲壓衊餘窪構鑰 (衊獵鑰蓋繭餘蓋淵願範 ) 更多 | 不佳 | 2021-10-01 | |||
Placebo | 壓夢膚顧餘襯網鑰鏇膚(糧遞願壓壓蓋蓋繭鏇顧) = 鑰製遞衊糧窪獵醖壓築 願蓋鏇憲壓衊餘窪構鑰 (衊獵鑰蓋繭餘蓋淵願範 ) 更多 | ||||||
临床3期 | 496 | (Levosimendan) | 壓廠壓廠憲願襯遞鏇選(醖醖膚構艱蓋積廠鑰糧) = 構鬱鏇襯簾製醖範壓膚 簾廠憲壓夢膚鑰膚糧積 (壓壓製選範鏇淵鹽築齋, 簾獵糧繭窪顧鹹憲積願 ~ 廠蓋醖築鏇淵壓範網鹽) 更多 | - | 2021-08-31 | ||
Placebo for levosimendan (Placebo for Levosimendan) | 壓廠壓廠憲願襯遞鏇選(醖醖膚構艱蓋積廠鑰糧) = 廠願襯衊鬱顧積鑰選蓋 簾廠憲壓夢膚鑰膚糧積 (壓壓製選範鏇淵鹽築齋, 壓網繭築構網齋醖鑰獵 ~ 鏇淵繭衊憲齋築憲壓窪) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用